Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.52−0.08 (-5.00%)
Close on Nov 18, 2026Market cap $12.53MP/E –Yield –
Lipocine revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Lipocine's revenue for the twelve months ending Jun 30, 2026 was $1.57M, down 62.7% year over year. For fiscal 2025 it was $1.98M, down 82.3% from the year before. The highest annual figure on record is $16.14M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.98M | -82.3% |
| FY2024 | Dec 31, 2024 | $11.20M | – |
| FY2023 | Dec 31, 2023 | -$2.85M | -670.2% |
| FY2022 | Dec 31, 2022 | $500.00K | -96.9% |
| FY2021 | Dec 31, 2021 | $16.14M | – |
| FY2020 | Dec 31, 2020 | $0 | -100.0% |
| FY2019 | Dec 31, 2019 | $164.99K | -61.5% |
| FY2018 | Dec 31, 2018 | $428.03K | – |
| FY2017 | Dec 31, 2017 | $0 | – |
| FY2016 | Dec 31, 2016 | $0 | – |
| FY2013 | Dec 31, 2013 | $0 | -100.0% |
| FY2012 | Dec 31, 2012 | $7.71M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $190.10K | -69.5% |
| Q1 FY2026 | Mar 31, 2026 | $119.40K | +27.2% |
| Q4 FY2025 | Dec 31, 2025 | $1.15M | -67.2% |
| Q3 FY2025 | Sep 30, 2025 | $114.57K | – |
| Q2 FY2025 | Jun 30, 2025 | $622.85K | +595.4% |
| Q1 FY2025 | Mar 31, 2025 | $93.86K | -98.8% |
| Q4 FY2024 | Dec 31, 2024 | $3.49M | +1515.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $89.57K | – |
| Q1 FY2024 | Mar 31, 2024 | $7.62M | +13751.9% |
| Q4 FY2023 | Dec 31, 2023 | $216.19K | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.12M | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $54.99K | -99.7% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
| Q2 FY2022 | Jun 30, 2022 | $500.00K | – |
| Q4 FY2021 | Dec 31, 2021 | $16.09M | – |
| Q3 FY2021 | Sep 30, 2021 | $54.99K | -66.7% |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $164.99K | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | -100.0% |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $428.03K | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
See a number that looks wrong?